Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004

Franco Aversa, Zwi N. Berneman, Franco Locatelli, Massimo F. Martelli, Yair Reisner, Antonio Tabilio, Andrea Velardi, Stanimir Vuk-Pavlovic

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Many patients with high-risk hematological malignancies or with incurable inborn errors do not have an HLA-matched sibling and cannot find an HLA-matched donor for an allogeneic hematopoietic stem cell transplantation (SCT). Transplantation strategies using mismatched haploidentical family donors have been an important development. Although the procedure has saved patients from certain death, it is still beset by major problems like life-threatening infections-due to profound immunodeficiency following T-cell depletion and to disease relapse. At every International Workshop on Haploidentical Transplants, new data are presented, showing how scientists are attempting to improve the outcomes of mismatched transplants while reducing the severity of complications. The fourth Workshop continues in this tradition of presenting ground-breaking research. It opened with presentations of the current results with unrelated volunteer and umbilical cord blood transplants and proceeded to a session with the results of haploidentical transplants in the world with series of patients with high-risk acute leukemia, ranging in number from well over 100 in Perugia, Italy, and 80 in Haifa, Israel, to smaller groups in Europe and the United States. The session on graft engineering presented the latest results in the search for the optimal graft. The graft-vs.-leukemia effect in the haploidentical transplant was discussed in depth. Subsequently, attention focussed on one of the major problems in haploidentical transplant, that is, the delay in immunological recovery. The Workshop closed with presentations on tolerance induction that was followed by the results of ongoing registration studies being performed by the Italian GIMEMA group and the European Bone Marrow Transplant group.

Original languageEnglish (US)
Pages (from-to)159-175
Number of pages17
JournalBlood Cells, Molecules, and Diseases
Volume33
Issue number3
DOIs
StatePublished - Nov 2004

Fingerprint

Italy
Transplants
Education
Leukemia
Tissue Donors
Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Israel
Fetal Blood
Siblings
Volunteers
Transplantation
Bone Marrow
T-Lymphocytes
Recurrence
Infection
Research

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Cite this

Aversa, F., Berneman, Z. N., Locatelli, F., Martelli, M. F., Reisner, Y., Tabilio, A., ... Vuk-Pavlovic, S. (2004). Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004. Blood Cells, Molecules, and Diseases, 33(3), 159-175. https://doi.org/10.1016/j.bcmd.2004.08.008

Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004. / Aversa, Franco; Berneman, Zwi N.; Locatelli, Franco; Martelli, Massimo F.; Reisner, Yair; Tabilio, Antonio; Velardi, Andrea; Vuk-Pavlovic, Stanimir.

In: Blood Cells, Molecules, and Diseases, Vol. 33, No. 3, 11.2004, p. 159-175.

Research output: Contribution to journalArticle

Aversa, F, Berneman, ZN, Locatelli, F, Martelli, MF, Reisner, Y, Tabilio, A, Velardi, A & Vuk-Pavlovic, S 2004, 'Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004', Blood Cells, Molecules, and Diseases, vol. 33, no. 3, pp. 159-175. https://doi.org/10.1016/j.bcmd.2004.08.008
Aversa, Franco ; Berneman, Zwi N. ; Locatelli, Franco ; Martelli, Massimo F. ; Reisner, Yair ; Tabilio, Antonio ; Velardi, Andrea ; Vuk-Pavlovic, Stanimir. / Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004. In: Blood Cells, Molecules, and Diseases. 2004 ; Vol. 33, No. 3. pp. 159-175.
@article{e8ed79e62995417b96a78a4c1e7c0c0a,
title = "Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004",
abstract = "Many patients with high-risk hematological malignancies or with incurable inborn errors do not have an HLA-matched sibling and cannot find an HLA-matched donor for an allogeneic hematopoietic stem cell transplantation (SCT). Transplantation strategies using mismatched haploidentical family donors have been an important development. Although the procedure has saved patients from certain death, it is still beset by major problems like life-threatening infections-due to profound immunodeficiency following T-cell depletion and to disease relapse. At every International Workshop on Haploidentical Transplants, new data are presented, showing how scientists are attempting to improve the outcomes of mismatched transplants while reducing the severity of complications. The fourth Workshop continues in this tradition of presenting ground-breaking research. It opened with presentations of the current results with unrelated volunteer and umbilical cord blood transplants and proceeded to a session with the results of haploidentical transplants in the world with series of patients with high-risk acute leukemia, ranging in number from well over 100 in Perugia, Italy, and 80 in Haifa, Israel, to smaller groups in Europe and the United States. The session on graft engineering presented the latest results in the search for the optimal graft. The graft-vs.-leukemia effect in the haploidentical transplant was discussed in depth. Subsequently, attention focussed on one of the major problems in haploidentical transplant, that is, the delay in immunological recovery. The Workshop closed with presentations on tolerance induction that was followed by the results of ongoing registration studies being performed by the Italian GIMEMA group and the European Bone Marrow Transplant group.",
author = "Franco Aversa and Berneman, {Zwi N.} and Franco Locatelli and Martelli, {Massimo F.} and Yair Reisner and Antonio Tabilio and Andrea Velardi and Stanimir Vuk-Pavlovic",
year = "2004",
month = "11",
doi = "10.1016/j.bcmd.2004.08.008",
language = "English (US)",
volume = "33",
pages = "159--175",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004

AU - Aversa, Franco

AU - Berneman, Zwi N.

AU - Locatelli, Franco

AU - Martelli, Massimo F.

AU - Reisner, Yair

AU - Tabilio, Antonio

AU - Velardi, Andrea

AU - Vuk-Pavlovic, Stanimir

PY - 2004/11

Y1 - 2004/11

N2 - Many patients with high-risk hematological malignancies or with incurable inborn errors do not have an HLA-matched sibling and cannot find an HLA-matched donor for an allogeneic hematopoietic stem cell transplantation (SCT). Transplantation strategies using mismatched haploidentical family donors have been an important development. Although the procedure has saved patients from certain death, it is still beset by major problems like life-threatening infections-due to profound immunodeficiency following T-cell depletion and to disease relapse. At every International Workshop on Haploidentical Transplants, new data are presented, showing how scientists are attempting to improve the outcomes of mismatched transplants while reducing the severity of complications. The fourth Workshop continues in this tradition of presenting ground-breaking research. It opened with presentations of the current results with unrelated volunteer and umbilical cord blood transplants and proceeded to a session with the results of haploidentical transplants in the world with series of patients with high-risk acute leukemia, ranging in number from well over 100 in Perugia, Italy, and 80 in Haifa, Israel, to smaller groups in Europe and the United States. The session on graft engineering presented the latest results in the search for the optimal graft. The graft-vs.-leukemia effect in the haploidentical transplant was discussed in depth. Subsequently, attention focussed on one of the major problems in haploidentical transplant, that is, the delay in immunological recovery. The Workshop closed with presentations on tolerance induction that was followed by the results of ongoing registration studies being performed by the Italian GIMEMA group and the European Bone Marrow Transplant group.

AB - Many patients with high-risk hematological malignancies or with incurable inborn errors do not have an HLA-matched sibling and cannot find an HLA-matched donor for an allogeneic hematopoietic stem cell transplantation (SCT). Transplantation strategies using mismatched haploidentical family donors have been an important development. Although the procedure has saved patients from certain death, it is still beset by major problems like life-threatening infections-due to profound immunodeficiency following T-cell depletion and to disease relapse. At every International Workshop on Haploidentical Transplants, new data are presented, showing how scientists are attempting to improve the outcomes of mismatched transplants while reducing the severity of complications. The fourth Workshop continues in this tradition of presenting ground-breaking research. It opened with presentations of the current results with unrelated volunteer and umbilical cord blood transplants and proceeded to a session with the results of haploidentical transplants in the world with series of patients with high-risk acute leukemia, ranging in number from well over 100 in Perugia, Italy, and 80 in Haifa, Israel, to smaller groups in Europe and the United States. The session on graft engineering presented the latest results in the search for the optimal graft. The graft-vs.-leukemia effect in the haploidentical transplant was discussed in depth. Subsequently, attention focussed on one of the major problems in haploidentical transplant, that is, the delay in immunological recovery. The Workshop closed with presentations on tolerance induction that was followed by the results of ongoing registration studies being performed by the Italian GIMEMA group and the European Bone Marrow Transplant group.

UR - http://www.scopus.com/inward/record.url?scp=7444263503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444263503&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2004.08.008

DO - 10.1016/j.bcmd.2004.08.008

M3 - Article

C2 - 15580686

AN - SCOPUS:7444263503

VL - 33

SP - 159

EP - 175

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 3

ER -